公开(公告)号：US20190144430A1

公开(公告)日：2019-05-16

申请号：US16247995

申请日：2019-01-15

Applicant: Genentech, Inc.

Inventor： Baihua HU ,  Vishal VERMA ,  Matthew VOLGRAF ,  Anthony ESTRADA ,  Joseph LYSSIKATOS

IPC: C07D403/04 ,  C07D231/12 ,  C07D401/04 ,  C07D231/20 ,  C07D239/26 ,  C07D231/16 ,  C07D213/61

Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

公开(公告)号：US20200171029A1

公开(公告)日：2020-06-04

申请号：US16568130

申请日：2019-09-11

Applicant: Genentech, Inc.

Inventor： Anthony ESTRADA ,  Alan G. OLIVERO ,  Snahel PATEL ,  Michael SIU ,  Joseph LYSSIKATOS

IPC: A61K31/506 ,  C07D471/08 ,  A61K45/06 ,  A61K31/5386 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/55 ,  A61K35/30 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/18 ,  C07D487/08 ,  C07D491/08 ,  C07D495/08 ,  C07D519/00 ,  A61K31/553 ,  C07D417/14 ,  C07D487/14 ,  C07D487/18 ,  A61K31/444

Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.

公开(公告)号：US20190144428A1

公开(公告)日：2019-05-16

申请号：US16250230

申请日：2019-01-17

Applicant: Genentech, Inc.

Inventor： Vishal VERMA ,  Daniel SHORE ,  Matthew VOLGRAF ,  Anthony A. ESTRADA ,  Joseph LYSSIKATOS

IPC: C07D401/14 ,  C07D403/14 ,  C07D403/12 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: The invention is concerned with the compounds of formula I: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.